- Home
- NSSC vs RCKT Comparison
NSSC vs RCKT Comparison
Compare NSSC & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NSSC
- RCKT
- Stock Information
- Founded
- NSSC 1969
- RCKT 1999
- Country
- NSSC United States
- RCKT United States
- Employees
- NSSC N/A
- RCKT N/A
- Industry
- NSSC Telecommunications Equipment
- RCKT Biotechnology: Pharmaceutical Preparations
- Sector
- NSSC Telecommunications
- RCKT Health Care
- Exchange
- NSSC Nasdaq
- RCKT Nasdaq
- Market Cap
- NSSC 899.1M
- RCKT 264.0M
- IPO Year
- NSSC N/A
- RCKT N/A
- Fundamental
- Price
- NSSC $30.83
- RCKT $2.99
- Analyst Decision
- NSSC Strong Buy
- RCKT Buy
- Analyst Count
- NSSC 6
- RCKT 13
- Target Price
- NSSC $34.50
- RCKT $18.50
- AVG Volume (30 Days)
- NSSC 287.7K
- RCKT 3.8M
- Earning Date
- NSSC 08-25-2025
- RCKT 08-04-2025
- Dividend Yield
- NSSC 1.82%
- RCKT N/A
- EPS Growth
- NSSC N/A
- RCKT N/A
- EPS
- NSSC 1.22
- RCKT N/A
- Revenue
- NSSC $181,227,000.00
- RCKT N/A
- Revenue This Year
- NSSC N/A
- RCKT N/A
- Revenue Next Year
- NSSC $6.02
- RCKT N/A
- P/E Ratio
- NSSC $25.24
- RCKT N/A
- Revenue Growth
- NSSC N/A
- RCKT N/A
- 52 Week Low
- NSSC $19.00
- RCKT $2.19
- 52 Week High
- NSSC $58.09
- RCKT $26.98
- Technical
- Relative Strength Index (RSI)
- NSSC 67.34
- RCKT 45.55
- Support Level
- NSSC $29.22
- RCKT $2.76
- Resistance Level
- NSSC $32.06
- RCKT $3.24
- Average True Range (ATR)
- NSSC 0.76
- RCKT 0.19
- MACD
- NSSC 0.12
- RCKT 0.17
- Stochastic Oscillator
- NSSC 82.80
- RCKT 74.85
About NSSC NAPCO Security Technologies Inc.
NAPCO Security Technologies Inc manufactures security products, encompassing access control systems, door-locking products, intrusion and fire alarm systems and video surveillance products. Its products are used for various applications which includes alarm systems like automatic communicators, combination control panels/digital communicators and digital keypad systems, fire alarm control panel and area detectors mainly used for commercial, residential, institutional, industrial and governmental uses. Geographically, the company derives a majority of its revenue from the United States.
About RCKT Rocket Pharmaceuticals Inc.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.